Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DXS6 | ISIN: US1711261057 | Ticker-Symbol:
NASDAQ
01.07.25 | 21:39
1,285 US-Dollar
-1,91 % -0,025
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PELTHOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PELTHOS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PELTHOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPelthos Therapeutics Inc. - 8-K, Current Report1
MiLigand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July246WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics...
► Artikel lesen
MiLigand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt5
MiLigand completes merger, Pelthos to launch molluscum treatment2
PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln
MiLigand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics78Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company...
► Artikel lesen
FrChannel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting2
FrChannel Therapeutics Corporation: Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement105FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment...
► Artikel lesen
14.05.EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models2
13.05.Channel Therapeutics Corp - 10-Q, Quarterly Report1
01.05.Channel Therapeutics Corp - 8-K, Current Report2
01.05.Channel Therapeutics Corporation: Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules1
17.04.Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi1
17.04.Ligand unit Pelthos to merge with Channel Therapeutics1
17.04.Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub398WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries...
► Artikel lesen
17.04.Channel Therapeutics Corp - 8-K, Current Report1
17.04.Ligand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics261Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI ZELSUVMI is an FDA-designated novel drug...
► Artikel lesen
27.03.Channel Therapeutics Corp - 10-K, Annual Report2
03.03.Channel Therapeutics Corp - 8-K, Current Report-
20.12.24Channel Therapeutics Corporation: Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine184FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics...
► Artikel lesen
18.12.24Channel Therapeutics Corporation: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model195FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1